0.4750GBp0.00%Mkt Cap: 6.81M GBpP/E: —Last update: 2026-05-13
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transp…
Industry Peers
Diagnostics & Researchloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
P/B0.60
P/S3.56
EV/EBITDA-0.13
EV/Revenue0.47
EPS (TTM)-0.02
EPS (Forward)0.00
Cash Flow & Leverage
FCF Yield-52.93%
FCF Margin-188.45%
Operating CF-6.02M GBp
CapEx (TTM)193.00K GBp
Net Debt/EBITDA0.03
Net Debt-185.00K GBp
Technical
SMA 500.5087 (-6.6%)
SMA 2000.6434 (-26.2%)
Beta1.30
S&P 52W Chg24.23%
Avg Vol (30d)1.40M
Avg Vol (10d)1.23M
Technical Indicators
RSI (14)28.9
MACD-0.0152
MACD Signal-0.0151
MACD Hist.-0.0000
BB Upper0.5443 GBp
BB Middle0.4950 GBp
BB Lower0.4457 GBp
BB Width19.92%
ATR (14)0.0582 GBp
Vol Ratio (20d)0.40x
52W Range
0.40006% of range1.750
52W High1.750 GBp
52W Low0.4000 GBp
Profitability
Gross Margin81.60%
EBITDA Margin0.00%
Profit Margin-175.92%
Oper. Margin-162.05%
ROE-111.57%
ROA-78.40%
Revenue Growth-42.70%
Earnings Growth—
Balance Sheet
Debt/Equity0.07
Current Ratio0.91
Quick Ratio0.68
Book Value/Sh0.0076 GBp
Cash/Share0.0020 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.1.51B
Float171.92M
Insiders3.86%
Institutions68.85%
Analyst Consensus
Rating—
Target (Mean)2.900 GBp
Target Range2.900 GBp – 2.900 GBp
# Analysts1
Company
Market Cap6.81M GBp
Enterprise Value906.44K GBp
Revenue (TTM)1.91M GBp
Gross Profit1.56M GBp
Net Income (TTM)-5.87M GBp
Revenue/Share0.0080 GBp
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees15
Last Price0.4750 GBp
CountryGB
SectorHealthcare
IndustryDiagnostics & Research
ISIN—